We are live on ! Find out more
PCVX icon

Vaxcyte
PCVX

Fund managers haven’t disclosed any holdings of PCVX yet.

PCVX Hedge Fund Activity: Q1 2026 in Review

336 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2026, worth a combined $9.44B — up 39% from $6.81B a quarter earlier.

Buyers outnumbered sellers: 71 funds opened new PCVX positions and 24 closed out — a net gain of 47 holders — while 129 added to existing stakes and 81 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $173M. The largest seller was Adage Capital Partners, cutting an estimated $74.6M.

  • 336 institutional investors held Vaxcyte (PCVX) as of Q1 2026, up from 295 in Q4 2025.
  • Funds reported $9.44B of Vaxcyte stock for Q1 2026, up 39% quarter-over-quarter.
  • 71 funds opened new Vaxcyte positions in Q1 2026 and 24 closed out, a net change of +47 holders.
  • The largest Vaxcyte buyer in Q1 2026 was Janus Henderson Group, an estimated $173M added.
  • The largest Vaxcyte seller in Q1 2026 was Adage Capital Partners, an estimated $74.6M sold.

Based on aggregated 13F filings for Q1 2026.